Molina Healthcare does cover GLP-1 medications, but what gets approved depends on why the drug is prescribed. For type 2 diabetes, GLP-1s like Ozempic, Trulicity, Mounjaro, and Victoza are covered across Molina’s Medicaid, Marketplace, and Medicare plans with prior authorization. For weight loss, most Molina plans exclude GLP-1s entirely, with narrow exceptions in a few states and for certain non-obesity medical uses.
Coverage for Type 2 Diabetes
When a GLP-1 is prescribed to manage blood sugar, it is a covered benefit under Molina, subject to the plan’s formulary and prior authorization rules. Which drugs are “preferred” varies by state. Passport by Molina Healthcare in Kentucky lists Ozempic, Trulicity, Victoza, Byetta, Mounjaro, and Rybelsus among its preferred agents.1Molina Healthcare. Passport by Molina Healthcare GLP-1 Criteria Change
To approve a GLP-1 for diabetes, Molina generally requires:
- A confirmed type 2 diabetes diagnosis, documented by ICD-10 code or an A1c of 6.5% or higher.
- No personal or family history of medullary thyroid carcinoma or MEN 2 syndrome.
- A dose at or below the maximum FDA-approved dose for diabetes.1Molina Healthcare. Passport by Molina Healthcare GLP-1 Criteria Change
Some plans add step therapy. A Texas Marketplace policy, for example, requires documentation that the patient tried and failed or cannot tolerate metformin, a sulfonylurea or TZD, and a DPP-4 inhibitor or SGLT2 inhibitor before a GLP-1 will be authorized.2Molina Healthcare. GLP-1 Receptor Agonist Prior Authorization Criteria Non-preferred GLP-1 agents typically require a trial and failure of at least two preferred agents for three months or more.1Molina Healthcare. Passport by Molina Healthcare GLP-1 Criteria Change
Weight Loss Is Generally Excluded
Across most of its plans, Molina treats drugs prescribed for weight loss as a benefit exclusion. This covers both Medicaid and Marketplace members and applies to Wegovy, Zepbound, and Saxenda when the indication is obesity alone. Molina cites Social Security Act Section 1927(d)(3)(A), which permits states to exclude coverage for drugs used for weight loss, weight gain, or cosmetic purposes.3Molina Healthcare. Wegovy (Semaglutide) Drug Coverage Criteria
Washington state Molina Medicaid explicitly lists “medications used for weight loss” among excluded drug categories, and the plan restricts GLP-1 receptor agonists to FDA-approved indications for type 2 diabetes.4Molina Healthcare. Molina Healthcare of Washington Medicaid Formulary5Molina Healthcare. Provider Bulletin: GLP-1 Receptor Agonists Illinois Medicaid takes the same line: Wegovy’s coverage criteria state that weight loss is excluded, and non-diabetes uses of listed GLP-1 agents are classified as experimental or investigational.6Molina Healthcare. Antidiabetic Agents Illinois Medicaid Coverage Criteria For Marketplace plans in most states, Zepbound is excluded for all weight-related indications, including weight reduction to treat obstructive sleep apnea.7Molina Healthcare. Zepbound (Tirzepatide) Coverage Criteria
State Exceptions for Weight Loss
Because Molina operates under state Medicaid and Marketplace contracts, a handful of states permit weight-loss coverage.
Virginia Medicaid
Molina’s Virginia plan covers Wegovy and Zepbound for weight loss when the member meets specific criteria. For adults, that means a BMI of 27 or higher with two or more risk factors such as heart disease, hypertension, or type 2 diabetes, or a BMI of 30 or higher. The plan also requires a prior trial and failure of a non-GLP-1 weight-loss drug, participation in nutritional counseling and physical activity, and no contraindications such as eating disorders or pregnancy. Initial authorization lasts six months, and renewal requires at least 5% weight loss from baseline.8Molina Healthcare. Virginia Weight Loss Service Authorization Form
Virginia Medicaid’s underlying service authorization criteria set higher BMI thresholds: at least 40, or at least 35 with two or more chronic conditions, plus a failed trial of a non-GLP-1 weight-loss medication within the prior six months, completed lifestyle interventions, and provider attestation that the obesity is disabling and life-threatening.9Virginia Medicaid (DMAS). Upcoming Changes to Service Authorization Criteria for Weight Loss Drugs
California and New Mexico Marketplace
Molina’s California Marketplace plans may cover weight-loss drugs when medically necessary for the treatment of morbid obesity, and the plan can require enrollment in a comprehensive weight-loss program. In New Mexico, Marketplace coverage extends to drugs that are medically necessary for the treatment of obesity and morbid obesity.7Molina Healthcare. Zepbound (Tirzepatide) Coverage Criteria
California Medi-Cal No Longer Covers Weight-Loss GLP-1s
Medi-Cal previously covered GLP-1s for weight loss, but that coverage ended on January 1, 2026, under state budget law SB 101. Prior authorizations for weight-loss use of Saxenda, Wegovy, and Zepbound expired on December 31, 2025, and new claims for weight-loss indications are denied. Narrow exceptions remain for members under age 21 under the federal EPSDT benefit, for Wegovy prescribed for cardiovascular disease or non-cirrhotic metabolic dysfunction-associated steatohepatitis, and for Zepbound for obstructive sleep apnea. GLP-1 drugs remain covered under Medi-Cal for type 2 diabetes, cardiovascular disease, and chronic kidney disease.10Medi-Cal Rx. Important Update: GLP-1s for Weight Loss Not a Covered Benefit11KFF Health News. California Medi-Cal Ends Coverage for GLP-1 Weight Loss Drugs
Non-Obesity Indications That Can Unlock Coverage
A denial for weight loss is not the end of the conversation if the member has a qualifying condition. Molina covers Wegovy to reduce the risk of major adverse cardiovascular events in adults who have:
- Established cardiovascular disease with a documented history of heart attack, stroke, or symptomatic peripheral arterial disease.
- A BMI of 27 or higher.
- No type 1 or type 2 diabetes.
- A prescriber who is a board-certified cardiologist or has consulted one.
- Standard cardiovascular risk-reduction care already in place, such as aspirin, lipid-lowering drugs, and antihypertensives.12Molina Healthcare. Wegovy (Semaglutide) Drug and Biologic Coverage Criteria
Initial authorization lasts six months. Continuation runs 12 months at a time and requires at least 85% adherence, no intolerable side effects, continued cardiovascular standard of care, and confirmation that the patient still does not have diabetes.12Molina Healthcare. Wegovy (Semaglutide) Drug and Biologic Coverage Criteria Zepbound for obstructive sleep apnea is also excluded under most Marketplace plans, so a sleep apnea diagnosis alone does not override the general weight-loss exclusion outside of specific state carve-outs.7Molina Healthcare. Zepbound (Tirzepatide) Coverage Criteria
Molina Medicare and the GLP-1 Bridge
Molina offers Medicare Advantage plans with Part D drug coverage in several states. The current formulary for Molina Medicare Complete Care should be checked directly on Molina’s Medicare site or by calling Member Services at (800) 665-3086.13Molina Healthcare. Molina Medicare Complete Care Formulary
For Medicare beneficiaries who want a GLP-1 for weight loss, a federal option exists in the second half of 2026. The Medicare GLP-1 Bridge program runs from July 1 through December 31, 2026, and covers Wegovy and Zepbound for weight loss through a centralized federal process that sits outside standard Part D. Molina Medicare members can access these drugs through the Bridge regardless of whether Molina’s own formulary covers them for that indication, and prior authorizations are handled by a central processor rather than by Molina. The Bridge is a temporary measure before the BALANCE Model launches in January 2027; members who want continued access in 2027 will need to enroll during open enrollment in a Part D plan that has opted into BALANCE.14CMS. Medicare GLP-1 Bridge
For non-weight-loss uses, such as Wegovy for cardiovascular risk reduction or Zepbound for obstructive sleep apnea, coverage goes through the standard Part D formulary and prior authorization process with Molina.14CMS. Medicare GLP-1 Bridge
How to Improve Your Chances of Approval
Prior authorization is almost always part of the process. A few steps help:
- Check your plan’s formulary first. Molina’s drug list varies by state and plan type. A pharmacist or Molina Member Services can confirm whether a specific drug is covered and on what tier.
- Prepare thorough clinical documentation: diagnosis, current BMI, recent A1c and other labs, medications already tried, and records of diet counseling or exercise programs.
- Work through step therapy before the request. If your plan requires trials of metformin or other agents first, get that history in the chart before the GLP-1 request is submitted.
- Frame around a covered indication. If weight loss is excluded but the patient has cardiovascular disease, kidney disease, or type 2 diabetes, the request should center on that condition.
- Appeal a denial in writing. Ask for the specific reason, address the missing criteria, and request a peer-to-peer review between the prescriber and Molina’s medical reviewer. If internal appeals fail, an external review by an independent physician may be available depending on the state.
Renewal typically requires evidence of progress. Weight-loss authorizations generally need at least 5% body weight reduction to continue past the initial six-month approval, though members with documented weight-related risk factors may qualify for renewal without meeting that threshold.8Molina Healthcare. Virginia Weight Loss Service Authorization Form